Bod Australia Ltd (ASX: BDA, “Bod”) has confirmed first prescriptions of the Company’s MediCabilis™ medicinal cannabis product have been received from UK patients participating in Project Twenty21.
What are the key highlights?
- Project Twenty21, is Europe’s largest medicinal cannabis registry, targeting 20,000 patients.
- Bod expects to supply a minimum of 1,000 patients during the registry with its unique 5% MediCabilis™ CBD product.
- MediCabilis™ will be sold for £150.00 per unit during Project Twenty21, which will add to Bod’s growing revenue profile.
- Now that the registry has commenced, a broad range of physicians and clinics across the UK can prescribe Bod’s MediCabilis™ to patients participating in Project Twenty21. This is a major milestone for the Company as it provides Bod with an additional sales channel for MediCabilis™.